Biological scaffold–mediated delivery of myostatin inhibitor promotes a regenerative immune response in an animal model of Duchenne muscular dystrophy

Recent studies have reported that the immune system significantly mediates skeletal muscle repair and regeneration. Additionally, biological scaffolds have been shown to play a role in polarizing the immune microenvironment toward pro-myogenic outcomes. Moreover, myostatin inhibitors are known to promote muscle regeneration and ameliorate fibrosis in animal models of Duchenne muscular dystrophy (DMD), a human disease characterized by chronic muscle degeneration. Biological scaffolds and myostatin inhibition can potentially influence immune-mediated regeneration in the dystrophic environment, but have not been evaluated together. Toward this end, here we created an injectable biological scaffold composed of hyaluronic acid and processed skeletal muscle extracellular matrix. This material formed a cytocompatible hydrogel at physiological temperatures in vitro. When injected subfascially above the tibialis anterior muscles of both WT and dystrophic mdx-5Cv mice, a murine model of DMD, the hydrogel spreads across the entire muscle before completely degrading at 3 weeks in vivo. We found that the hydrogel is associated with CD206+ pro-regenerative macrophage polarization and elevated anti-inflammatory cytokine expression in both WT and dystrophic mice. Co-injection of both hydrogel and myostatin inhibitor significantly increased FoxP3+ regulatory T cell modulation and Foxp3 gene expression in the scaffold immune microenvironment. Finally, delivery of myostatin inhibitor with the hydrogel increased its bioactivity in vivo, and transplantation of immortalized human myoblasts with the hydrogel promoted their survival in vivo. This study identifies a key role for biological scaffolds and myostatin inhibitors in modulating a pro-regenerative immune microenvironment in dystrophic muscle.

[1]  C. Morris,et al.  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF‐06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects , 2018, Clinical pharmacology in drug development.

[2]  P. Chan,et al.  Application of Quantitative Pharmacology Approaches in Bridging Pharmacokinetics and Pharmacodynamics of Domagrozumab From Adult Healthy Subjects to Pediatric Patients With Duchenne Muscular Disease , 2018, Journal of clinical pharmacology.

[3]  Mark Johnson,et al.  A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys , 2017, Skeletal Muscle.

[4]  P. Muñoz-Cánoves,et al.  Fibrosis development in early-onset muscular dystrophies: Mechanisms and translational implications. , 2017, Seminars in cell & developmental biology.

[5]  M. Tarnopolsky,et al.  Myostatin inhibitor ACE‐031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo‐controlled clinical trial , 2017, Muscle & nerve.

[6]  J. Tidball Regulation of muscle growth and regeneration by the immune system , 2017, Nature Reviews Immunology.

[7]  A. Pestronk,et al.  Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy , 2016, Neurology.

[8]  J. Chamberlain,et al.  Prosurvival Factors Improve Functional Engraftment of Myogenically Converted Dermal Cells into Dystrophic Skeletal Muscle. , 2016, Stem cells and development.

[9]  P. Doevendans,et al.  Cardiac-Derived Extracellular Matrix Enhances Cardiogenic Properties of Human Cardiac Progenitor Cells , 2016, Cell transplantation.

[10]  Jenna L. Dziki,et al.  Immunomodulation and Mobilization of Progenitor Cells by Extracellular Matrix Bioscaffolds for Volumetric Muscle Loss Treatment. , 2016, Tissue engineering. Part A.

[11]  Drew M. Pardoll,et al.  Design, clinical translation and immunological response of biomaterials in regenerative medicine , 2016 .

[12]  J. Elisseeff,et al.  Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells , 2016, Science.

[13]  J. Cavaillon,et al.  Comparative Study of Injury Models for Studying Muscle Regeneration in Mice , 2016, PloS one.

[14]  N. Bursac,et al.  Synergizing Engineering and Biology to Treat and Model Skeletal Muscle Injury and Disease. , 2015, Annual review of biomedical engineering.

[15]  E. Hoffman,et al.  Immune-mediated pathology in Duchenne muscular dystrophy , 2015, Science Translational Medicine.

[16]  J. Bertrand,et al.  Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice , 2015, Nature Medicine.

[17]  L. Leinwand,et al.  Developmental myosins: expression patterns and functional significance , 2015, Skeletal Muscle.

[18]  R. Markwald,et al.  Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer , 2015, Front. Immunol..

[19]  Elizabeth G Loboa,et al.  Naturally derived and synthetic scaffolds for skeletal muscle reconstruction. , 2015, Advanced drug delivery reviews.

[20]  D. Mooney,et al.  Biomaterial-based delivery for skeletal muscle repair. , 2015, Advanced drug delivery reviews.

[21]  C. Bearzi,et al.  In vivo generation of a mature and functional artificial skeletal muscle , 2015, EMBO molecular medicine.

[22]  G. Arya,et al.  Biomimetic Material-Assisted Delivery of Human Embryonic Stem Cell Derivatives for Enhanced In Vivo Survival and Engraftment. , 2015, ACS biomaterials science & engineering.

[23]  J. Bluestone,et al.  The immune system in Duchenne muscular dystrophy: Friend or foe , 2015, Rare diseases.

[24]  A. Lu,et al.  Online Self-Report Data for Duchenne Muscular Dystrophy Confirms Natural History and Can Be Used to Assess for Therapeutic Benefits , 2014, bioRxiv.

[25]  J. Bluestone,et al.  Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy , 2014, Science Translational Medicine.

[26]  R. Gilbert,et al.  A protocol for rheological characterization of hydrogels for tissue engineering strategies. , 2014, Journal of biomedical materials research. Part B, Applied biomaterials.

[27]  Douglas J. Weber,et al.  An Acellular Biologic Scaffold Promotes Skeletal Muscle Formation in Mice and Humans with Volumetric Muscle Loss , 2014, Science Translational Medicine.

[28]  P. Hogan,et al.  Cost of illness for neuromuscular diseases in the United States , 2014, Muscle & nerve.

[29]  J. Davie,et al.  Interferon-γ Resets Muscle Cell Fate by Stimulating the Sequential Recruitment of JARID2 and PRC2 to Promoters to Repress Myogenesis , 2013, Science Signaling.

[30]  C. Benoist,et al.  A Special Population of Regulatory T Cells Potentiates Muscle Repair , 2013, Cell.

[31]  J. Mendell,et al.  Eteplirsen for the treatment of Duchenne muscular dystrophy , 2013, Annals of neurology.

[32]  B. O’Rourke,et al.  Hyaluronic acid-human blood hydrogels for stem cell transplantation. , 2012, Biomaterials.

[33]  S. Calve,et al.  Hyaluronic acid, HAS1, and HAS2 are significantly upregulated during muscle hypertrophy. , 2012, American journal of physiology. Cell physiology.

[34]  Jiangyang Zhang,et al.  Inhibition of myostatin reverses muscle fibrosis through apoptosis , 2012, Journal of Cell Science.

[35]  Cindy Hamil,et al.  Evidence‐based path to newborn screening for duchenne muscular dystrophy , 2012, Annals of neurology.

[36]  J. Tremblay,et al.  Fibrin Gel Improves the Survival of Transplanted Myoblasts , 2012, Cell transplantation.

[37]  H. Vandenburgh,et al.  The role of multifunctional delivery scaffold in the ability of cultured myoblasts to promote muscle regeneration. , 2011, Biomaterials.

[38]  J. Tidball,et al.  IFN-γ Promotes Muscle Damage in the mdx Mouse Model of Duchenne Muscular Dystrophy by Suppressing M2 Macrophage Activation and Inhibiting Muscle Cell Proliferation , 2011, The Journal of Immunology.

[39]  A. Macke,et al.  mdx(⁵cv) mice manifest more severe muscle dysfunction and diaphragm force deficits than do mdx Mice. , 2011, The American journal of pathology.

[40]  K. Wagner,et al.  Regeneration versus fibrosis in skeletal muscle , 2011, Current opinion in rheumatology.

[41]  J. Davie,et al.  Gamma Interferon Modulates Myogenesis through the Major Histocompatibility Complex Class II Transactivator, CIITA , 2011, Molecular and Cellular Biology.

[42]  J. Mendell,et al.  The Muscular Dystrophies: Distinct Pathogenic Mechanisms Invite Novel Therapeutic Approaches , 2011, Current rheumatology reports.

[43]  F. Muntoni,et al.  Contribution of Human Muscle-Derived Cells to Skeletal Muscle Regeneration in Dystrophic Host Mice , 2011, PloS one.

[44]  A. Mai,et al.  TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. , 2010, Cell stem cell.

[45]  Michael C. Ostrowski,et al.  TNF Inhibits Notch-1 in Skeletal Muscle Cells by Ezh2 and DNA Methylation Mediated Repression: Implications in Duchenne Muscular Dystrophy , 2010, PloS one.

[46]  K. Wagner,et al.  Myostatin Directly Regulates Skeletal Muscle Fibrosis* , 2008, Journal of Biological Chemistry.

[47]  A. Pestronk,et al.  A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy , 2008, Annals of neurology.

[48]  J. Shay,et al.  Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin‐dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies , 2007, Aging cell.

[49]  M. Pangalos,et al.  Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis , 2006, Neurobiology of Disease.

[50]  T. Braun,et al.  Myostatin mutation associated with gross muscle hypertrophy in a child. , 2004, The New England journal of medicine.

[51]  Quazi Shakey,et al.  Gdf-8 Propeptide Binds to GDF-8 and Antagonizes Biological Activity by Inhibiting GDF-8 Receptor Binding , 2001, Growth factors.

[52]  Se-Jin Lee,et al.  Myostatin and the control of skeletal muscle mass. , 1999, Current opinion in genetics & development.

[53]  Se-Jin Lee,et al.  Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member , 1997, nature.

[54]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.